Exane Derivatives’s Acadia Pharmaceuticals ACAD Stock Holding History

Exane Derivatives’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-604	Closed	-$14.5K	–	1046
2021 Q2	$14.5K	Buy	+604	New	+$13.6K	﹤0.01%	733
2021 Q1	–	Sell	-5,505	Closed	-$294K	–	883
2020 Q4	$294K	Buy	5,505 +2,580	+88%	+$128K	0.09%	246
2020 Q3	$121K	Sell	2,925 -1,066	-27%	-$46K	0.03%	277
2020 Q2	$193K	Sell	3,991 -727	-15%	-$34.9K	0.05%	214
2020 Q1	$199K	Buy	+4,718	New	+$194K	0.06%	200

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Exane Derivatives's ACAD Position: Q3 2021 in Review

Exane Derivatives sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 604 shares — an estimated $14.5K sold.

Exane Derivatives first reported a position in ACAD in Q1 2020 and held it in 5 quarters. The position peaked at $294K in Q4 2020. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

Exane Derivatives reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 604 Acadia Pharmaceuticals shares in Q3 2021, an estimated $14.5K.
Exane Derivatives first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 5 quarters.
Exane Derivatives's Acadia Pharmaceuticals position peaked at $294K in Q4 2020.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.